In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase

In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase

Show other versions (1)

Background & Objective: Oral chelators such as deferasirox are used to treat iron overload caused by blood transfusion. Considering the significant role of liver in detoxification and drug metabolism as well as the importance of catalase as a key enzyme in detoxification, this study was performe...

Full description

Bibliographic Details
Main Authors:	Maryam Moradi, Adeleh Divsalar, Maryam Saidifar, Ali Akbar Saboury, Mohammad Tahmaseb
Format:	Article
Language:	English
Published:	Fasa University of Medical Sciences 2014-11-01
Series:	Journal of Advanced Biomedical Sciences
Subjects:	deferasirox catalase kinetic structure fluorescence
Online Access:	http://jabs.fums.ac.ir/article-1-394-en.pdf

Similar Items

In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase
by: Maryam Moradi, et al.
Published: (2014-11-01)

Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso
by: Nadia Karina Aguilar Hinojosa, et al.
Published: (2023-08-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

Renal function in patients with thalassemia major receiving Exjade® dispersible tablets and a new film-coated tablet formulation of deferasirox (Nanojade®)
by: Vahid Falahati, et al.
Published: (2022-01-01)

Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy
by: Alba Rodríguez-García, et al.
Published: (2019-10-01)

Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia
by: Rasul Jameel Ali, et al.
Published: (2020-12-01)

Pengaruh Deferasirox Terhadap Kadar T4 dan TSH Pada B-Thalassemia Mayor dengan Kadar Ferritin Tinggi
by: Dewi Ratih P, et al.
Published: (2016-11-01)

Synthesis and Characterization of Deferasirox PLGA Nanoparticles and Investigation of Toxicity in Cell Model
by: Hamidreza Mohammadi, et al.
Published: (2022-11-01)

Deferasirox Nanosuspension Loaded Dissolving Microneedles for Intradermal Delivery
by: Hafsa Shahid Faizi, et al.
Published: (2022-12-01)

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
by: Hana Votavova, et al.
Published: (2021-01-01)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
by: Laura Galeotti, et al.
Published: (2021-08-01)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial
by: Mohammad Reza Golpayegani, et al.
Published: (2019-01-01)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi P, et al.
Published: (2015-12-01)

Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review
by: Martin Scoglio, et al.
Published: (2021-12-01)

Kinetic Parameters Analysis of Liver and Kidney Catalase Under The Influence of Cadmium and Mercury In Vitro
by: Ellsa Anggun Karantika, et al.
Published: (2016-05-01)

A Deferasirox Derivative That Acts as a Multifaceted Platform for the Detection and Quantification of Fe<sup>3+</sup>
by: Axel Steinbrueck, et al.
Published: (2021-03-01)

Acute liver failure in a pediatric patient with congenital dyserythropoietic anemia type I treated with deferasirox
by: Galina Ling, et al.
Published: (2015-09-01)

Juvenile Hemochromatosis: Rheumatic Manifestations of 2 Sisters Responding to Deferasirox Treatment. A Case Series and Literature Review
by: Alqanatish J, et al.
Published: (2021-01-01)

Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
by: Bourafai-Aziez A, et al.
Published: (2021-12-01)

Deferasirox Targeting Ferroptosis Synergistically Ameliorates Myocardial Ischemia Reperfusion Injury in Conjunction With Cyclosporine A
by: Kosei Ishimaru, et al.
Published: (2024-01-01)

Comparison of the Mean Serum Ferritin Levels in Thalassaemia Major Patients after Giving Deferasirox and Deferoxamine
by: Seema Aftab, et al.
Published: (2017-12-01)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
by: Trisha E. Wong, et al.
Published: (2021-09-01)

Immobilization and characterization of bovine liver catalase on eggshell
by: ÖZLEM ALPTEKİN, et al.
Published: (2008-06-01)

Immobilization and characterization of bovine liver catalase on eggshell
by: Alptekin Özlem, et al.
Published: (2008-01-01)

Use of Deferasirox Film-Coated Tablets in Pediatric Patients with Transfusion Dependent Thalassemia: A Single Center Experience
by: Alkistis Adramerina, et al.
Published: (2022-02-01)

M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer
by: Yongmei Zhao, et al.
Published: (2021-09-01)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions
by: Chalmers AW, et al.
Published: (2016-02-01)

Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial
by: Mohammadreza Rafati, et al.
Published: (2022-01-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Duodenal perforation caused by deferasirox “case report”
by: Mohammmed Al Blooshi, et al.
Published: (2023-07-01)

Comparison of the Effects of Deferasirox (Nanojade®) and Deferoxamine (Desferal®) on Serum Ferritin Level Changes in Major Beta-Thalassemia Patients: A Randomized Clinical Trial
by: saeedeh Khorashadi Zadeh, et al.
Published: (2023-12-01)

Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells
by: Chiara Calabrese, et al.
Published: (2020-10-01)

Dual molecular mechanism of catalase in cancer and resistance to chemotherapy
by: Gholamian A, et al.
Published: (2016-06-01)

Deferasirox in Patients with Chronic Kidney Disease: Assessing the Potential Benefits and Challenges
by: Nashwan AJ, et al.
Published: (2023-11-01)

Long-term hematological response in 5q- syndrome after lenalidomide suspension and further improvement by deferasirox.
by: Pasquale Niscola
Published: (2014-08-01)

Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India
by: Isita Tripathy, et al.
Published: (2022-09-01)

A Solid Ultra Fine Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) of Deferasirox for Improved Solubility: Optimization, Characterization, and In Vitro Cytotoxicity Studies
by: Alaa Alghananim, et al.
Published: (2020-07-01)

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
by: Shogo Amano, et al.
Published: (2020-07-01)

Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias
by: Ali T. Taher, et al.
Published: (2018-11-01)